ILUVIEN marketing authorisation in Austria

ILUVIEN marketing authorisation in Austria

Alimera Sciences has announced that the Austrian Agency for Health and Food Safety, (Osterreichische Agentur fur Gesundheit und Ernahrungssicherheit (AGES), has granted marketing authorisation to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. 'We are excited to receive this marketing authorisation and pleased that DME patients in Austria will have this therapy available to them. We look forward to receiving the additional expected approvals from the UK and other concerned member states as we continue on track with our commercialisation plans in the EU,' said Dan Myers, president and chief executive officer, Alimera Sciences.

www.alimerasciences.com 

Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...